Zheng Quan Zhi Xing·2025-06-20 13:36Core Viewpoint - The legal opinion letter confirms that InnoCare Pharma Limited's 2025 Annual General Meeting (AGM) was convened and conducted in compliance with relevant Chinese laws and regulations, ensuring the validity of the meeting and its resolutions [2][12]. Group 1: Meeting Procedures - The AGM was announced on April 29, 2025, in accordance with the requirements of the Shanghai Stock Exchange and relevant media [5][6]. - The meeting utilized a combination of on-site and online voting, with the on-site meeting held on June 20, 2025, in Beijing [6][11]. - The notice for the AGM was published more than 20 days prior to the meeting, complying with the regulations [6][12]. Group 2: Voting Participation and Qualifications - A total of 17 shareholders participated in the on-site voting, representing 662,698,486 shares, which is 37.6345% of the total voting shares [7][9]. - The total number of participants, including online voters, was 222, with A-share shareholders representing 3.1417% of the total voting shares [7][9]. - The qualifications of the participating shareholders were verified by the Shanghai Stock Exchange and Hong Kong Central Securities Depository [8][9]. Group 3: Voting Procedures and Results - The AGM addressed several resolutions, including the approval of the 2024 annual report and the re-election of directors [10][11]. - All resolutions were passed by ordinary resolution, requiring a simple majority vote [11][12]. - The voting procedures and results were confirmed to be in compliance with the relevant regulations of the Shanghai Stock Exchange and the Cayman Islands [12][13].